The short answer
Checkpoint inhibitors can inflame the lungs. Pneumonitis shows up as a new or worsening cough, breathlessness at less effort than before, or chest pain. Call your doctor right away, or get emergency care, if you notice these. For trouble breathing, call 911. Name your immunotherapy drug at any urgent visit.
Immune-mediated pneumonitis occurred in 3.4% of patients in pembrolizumab labeling, and was fatal in 0.1%.
Measure against your own recent baseline: stopping halfway up stairs you used to climb easily is the change to report.
A new or worsening cough, shortness of breath or chest pain needs a call to your doctor right away, or emergency care. Call 911 if you have trouble breathing.
Name your checkpoint inhibitor at any urgent visit, and say when you last had it.
Watch the full explainer
Immunotherapy side effects: what's normal and when to call right away
Captioned, with chapters. Pressing play loads the video from YouTube’s privacy-enhanced player (youtube-nocookie.com). Educational only, not medical advice.
On this page
Choose how you want to read this
The whole article, with every detail and caution.
This page is for people on checkpoint inhibitor immunotherapy who notice a new cough or new breathlessness, and for the people caring for them. It explains what lung inflammation from these drugs feels like, and how fast to report it.
Immune checkpoint inhibitors help your immune system attack cancer. They work by removing some of the controls that normally hold it back. Sometimes the immune system also turns on healthy organs. The National Cancer Institute (NCI) calls this organ-related inflammation. It names each type after the organ, using the ending "-itis." Inflammation in the lungs is called pneumonitis.
What pneumonitis feels like
NCI describes it in one sentence: "Inflammation in the lungs, called pneumonitis, can cause you to feel short of breath and have a bad cough."
That is a short list, and the words matter. Two things count here:
A new cough, or a cough that is getting worse. The patient information from the U.S. National Library of Medicine for pembrolizumab lists "New or worsening cough, shortness of breath, chest pain" among the symptoms that need urgent attention. A cough you have had for years is not the signal. A cough that started after you began immunotherapy is. So is one that has changed.
Breathlessness at less effort than before. Use this measure, because "short of breath" is easy to talk yourself out of. Compare against your own recent baseline. Say last month you climbed a flight of stairs without stopping, and this week you stop halfway. That is the change worth reporting, even if you can still get up the stairs. Getting breathless walking across a room, or while sitting still, is further along the same line.
Chest pain or chest discomfort appears alongside cough and breathlessness in the same list of symptoms to act on.
Why it can be quiet at the start
Pneumonitis does not always announce itself. In FDA labeling for pembrolizumab, immune-mediated pneumonitis occurred in 3.4% of patients treated, including fatal cases in 0.1%. Do not use "I feel mostly fine" as a reason to hold back a new cough. If a scan report mentions changes in your lungs, ask your team whether pneumonitis is being considered.
How fast to report it
The instruction in the National Library of Medicine's pembrolizumab information is not gentle, and it should not be softened here: "Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment." In plain words, call right away.
The same phrasing appears in the ipilimumab patient information. There, "cough, chest pain, or shortness of breath" is followed by the instruction to "call your doctor immediately or get emergency medical treatment."
NCI adds that your oncologist "may advise you to call him or her first about inflammatory symptoms, or you may be advised to seek emergency medical care." Find out at your next visit which of these your team wants. Ask where to call outside clinic hours too. Then you are not deciding it while breathless.
If you go to an emergency department or urgent care, say the name of your immunotherapy drug and when you last received it. NCI says other medical staff need to know you are receiving immunotherapy.
When to get help sooner
- Call 911 or go to the nearest emergency department if you have trouble breathing. Also call 911 if you are suddenly confused or cannot be woken. Do not drive yourself.
- Call your care team right away, day or night, if you have a new or worsening cough, more shortness of breath than usual, or any chest pain. If you cannot reach the team quickly, go to an emergency department. Say the name of your immunotherapy drug.
Why steroids are used to treat it
The underlying problem is an immune response that has gone too far. So the treatment targets the immune system. NCI states: "Sometimes these side effects are managed with medicines, such as steroids, that work to slow down an overactive immune response."
In pembrolizumab labeling, systemic corticosteroids were required in 67% of patients who developed pneumonitis. The label describes a steroid such as prednisone, given until the reaction improves. It is then lowered slowly over at least a month.
Both the size of the dose and the speed of the taper are the team's decisions, and the taper is not one to shorten on your own. Pneumonitis led to the drug being permanently discontinued in 1.3% of patients, and temporarily withheld in 0.9%.
Symptoms can start after your last dose
Lung symptoms can begin after treatment has ended. FDA labeling states that "immune-mediated adverse reactions can occur at any time after starting treatment with a PD-1/PD-L1 blocking antibody." They usually appear during treatment, but they "can also manifest after discontinuation." A new cough or new breathlessness months after your final infusion still belongs to your oncology team.
Sources
- National Cancer Institute — Immunotherapy and Organ-Related Inflammation: https://www.cancer.gov/about-cancer/treatment/side-effects/organ-inflammation
- MedlinePlus (National Library of Medicine) — Pembrolizumab Injection: https://medlineplus.gov/druginfo/meds/a614048.html
- MedlinePlus (National Library of Medicine) — Ipilimumab Injection: https://medlineplus.gov/druginfo/meds/a611023.html
- U.S. Food and Drug Administration — KEYTRUDA (pembrolizumab) prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287

Common questions
What is pneumonitis?
Immune checkpoint inhibitors work by removing some of the controls that normally hold the immune system back. Sometimes the immune system also turns on healthy organs, which NCI calls organ-related inflammation and names after the organ using the ending -itis. Inflammation in the lungs is pneumonitis, and NCI says it can make you feel short of breath and have a bad cough.
Which cough should I report?
One that started after you began immunotherapy, or one that has changed or is getting worse. A cough you have had for years is not the signal. The pembrolizumab patient information lists new or worsening cough, shortness of breath and chest pain among the symptoms that need urgent attention.
How do I judge whether I am more breathless?
Compare against your own recent baseline, because short of breath is easy to talk yourself out of. If last month you climbed a flight of stairs without stopping and this week you stop halfway, that is the change worth reporting, even if you can still get up the stairs. Getting breathless walking across a room, or while sitting still, is further along the same line.
Do I call the team or go to the emergency department?
Ask in advance. NCI says your oncologist may advise you to call first about inflammatory symptoms, or may advise you to seek emergency medical care, so find out which your team wants and where to call outside clinic hours. If you do go in, say the name of your immunotherapy drug and when you last received it. NCI says other medical staff need to know you are receiving immunotherapy. If you have trouble breathing, call 911.
Can this start after my last dose?
Yes. FDA labeling states that immune-mediated adverse reactions can occur at any time after starting treatment with a PD-1/PD-L1 blocking antibody. They usually appear during treatment, but they can also manifest after discontinuation. A new cough or new breathlessness months after your final infusion still belongs to your oncology team.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Talk with a trained specialist or navigator
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Fever of 100.4°F (38°C) or higher during chemo, severe pain, or trouble breathing: call your cancer care team right away, day or night. Call 911 for an emergency.
